Arcus Biosciences Inc (NYSE:RCUS) President Juan C. Jaen acquired 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was purchased at an average cost of $7.59 per share, with a total value of $113,850.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
NYSE:RCUS traded down $0.36 during mid-day trading on Friday, hitting $8.17. 64,649 shares of the company traded hands, compared to its average volume of 178,713. The company has a fifty day moving average of $8.43. Arcus Biosciences Inc has a one year low of $7.15 and a one year high of $16.06. The company has a market cap of $363.85 million, a price-to-earnings ratio of -5.71 and a beta of 1.01.
Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.07). Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.25 million. Sell-side analysts forecast that Arcus Biosciences Inc will post -1.64 earnings per share for the current fiscal year.
Several analysts recently commented on RCUS shares. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Citigroup cut their price target on Tremont Mortgage Trust from $9.50 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, June 5th. Finally, Svb Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Arcus Biosciences presently has a consensus rating of “Buy” and an average target price of $16.56.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Article: Management Fee
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.